New Triple Agonist Achieves Potent Weight Loss with Weaker GIPR Activation

The treatment of obesity and type 2 diabetes has seen significant advancements with agonists targeting the glucagon-like peptide 1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). While triple activation of these receptors is a promising strategy, it remains unclear whether potent activation of all three receptors is truly necessary for optimal therapeutic efficacy.

The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose-dependent insulinotropic polypeptide receptor). Despite this reduced GIPR potency, the compound exhibited remarkable metabolic benefits. Preliminary mechanistic investigations also revealed that xGLP/GCG/GIP-32 operates via biased agonism towards the GIPR and GCGR, meaning it preferentially activates certain signaling pathways over others at these receptors, contributing to its unique therapeutic profile. > xGLP/GCG/GIP-32 demonstrated superior weight loss effects when compared directly to the established dual GLP-1R/GIPR agonist, tirzepatide, in preclinical studies. Furthermore, this novel triple agonist achieved metabolic efficacy that was similar to retatrutide, a known potent triple agonist, highlighting its potential despite a different receptor activation balance.